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Maml1 acts cooperatively with Gli proteins to regulate
sonic hedgehog signaling pathway
Roberta Quaranta1,6, Maria Pelullo1,6, Sabrina Zema1, Francesca Nardozza1, Saula Checquolo2, Dieter Matthias Lauer1,7,
Francesca Bufalieri1, Rocco Palermo3, Maria Pia Felli4, Alessandra Vacca4, Claudio Talora1, Lucia Di Marcotullio1,5,
Isabella Screpanti*,1,3,5,6 and Diana Bellavia*,1,6
Sonic hedgehog (Shh) signaling is essential for proliferation of cerebellar granule cell progenitors (GCPs) and its misregulation is
linked to various disorders, including cerebellar cancer medulloblastoma. The effects of Shh pathway are mediated by the Gli
family of transcription factors, which controls the expression of a number of target genes, including Gli1. Here, we identify
Mastermind-like 1 (Maml1) as a novel regulator of the Shh signaling since it interacts with Gli proteins, working as a potent
transcriptional coactivator. Notably, Maml1 silencing results in a significant reduction of Gli target genes expression, with a
negative impact on cell growth of NIH3T3 and Patched1−/− mouse embryonic fibroblasts (MEFs), bearing a constitutively active
Shh signaling. Remarkably, Shh pathway activity results severely compromised both in MEFs and GCPs deriving from Maml1−/−
mice with an impairment of GCPs proliferation and cerebellum development. Therefore Maml1−/− phenotype mimics aspects of
Shh pathway deficiency, suggesting an intrinsic requirement for Maml1 in cerebellum development. The present study shows a
new role for Maml1 as a component of Shh signaling, which plays a crucial role in both development and tumorigenesis.
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Hedgehog (Hh) signaling has been implicated in the regulation
of key events during developmental processes.1 Hh pathway
is controlled by extracellular ligands (Sonic, Indian and Desert
hedgehog) through interaction with the receptor Patched
(Ptch), thereby enhancing Smoothened (Smo) function, which
activates Gli transcription factors.2 Transcriptional activation is
largely derived from Gli1 and Gli2, whereas Gli3 mainly shows
repressor activity in the absence of ligand. Gli1, the final and
strongest transcriptional activator,3 is both the downstream
effector and a target gene of the pathway, representing a
feedback loop that serves as a readout of Hh activity.1,4,5
Signaling through Smo causes nuclear translocation of Gli1,
able to induce the expression of pro-proliferative target genes,
including Cyclins D1 and D2 (refs 6,7), which directly promote
the entry into the cell cycle and DNA replication. Sonic
hedgehog (Shh) pathway has a pivotal role in controlling
embryonic patterning and is a master regulator of cerebellar
granule cell progenitors (GCPs) development.8
Cerebellar development is a finely orchestrated process that
produces an elaborate set of folia separated by fissures. The
process of foliation begins during the prenatal period with the
formation of four principal fissures, which divide the cerebel-
lum into five cardinal lobes.9 Shh secreted by Purkinje cells
(PCs) from E17.5 onward in the mouse is a key GCPsmitogen
that promotes proliferation10,11 and sustains normal cerebel-
lum foliation.12,13 Especially, it has been shown that Shh
signaling spatially and temporarily correlates with fissures
formation, regulating the number of folia through its influence
on GCPs expansion.12 Proliferation of granule cells and the
process of cerebellar development appear to be strongly
related to one another.12,14,15 Indeed, a deregulated Shh
signaling alters the development of GCPs making them
hyperproliferative and susceptible to malignant transformation
into medulloblastoma (MB), the most frequent childhood brain
tumor.8,16 The biological and pathogenic importance of Shh
signaling emphasizes the need to tightly control its action.
In this study, we identify Mastermind-like 1 (Maml1) as a
novel regulator of Shh signaling. In mammals, Maml1
(refs 17,18) belongs to a family of proteins, also including
Maml2 and Maml3 (refs 19,20), which act as transcriptional
coactivators for Notch signaling,21 an evolutionarily conserved
pathway.22–24 Maml1 has been recently shown to act as a
coactivator in other cell signaling pathways, including p53
(ref. 25), MEF2C26 and β-catenin,27 in a Notch-independent
manner. These findings suggest broader roles for Maml1
protein in regulating important physiological processes.
Here, we present evidence that Maml1 enforces the Shh
pathway, via a novel Notch-independent mechanism. At the
molecular level, we found that Maml1 physically interacts with
Gli1 and Gli2, promoting Shh-dependent transcriptional
events. In addition, we show that Maml1 silencing disrupts
Shh signaling with a significant reduction of Gli target genes
expression. Noteworthy, in mouse embryo fibroblasts (MEFs)
and GCPs deriving from Maml1−/− mutant mice, the Shh
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pathway is strongly compromised, resulting in a decreased
expression of Gli1 and Gli2, which impacts on GCPs
proliferation and cerebellum development.
Results
Maml1/Gli1 protein–protein interaction reinforces the
activation of Shh target genes. Based on Maml1 functions
as a transcriptional coactivator in several signaling
pathways28 and being its expression significantly higher in
the cerebellum than in other tissues (Supplementary
Figure S1a), we sought to examine Maml1 role in the
activation of the Shh pathway. To address this issue,
HEK293T cells were cotransfected with 12xGli-luc (an
artificial Gli reporter containing 12 copies of Gli-responsive
elements) or Patched1-luc and vectors expressing Gli1 or
Gli2 alone and in combination with Maml1. Figure 1a shows
that Maml1 strongly cooperates with Gli proteins to potentiate
both of Shh-responsive reporters. Moreover, these results
confirm that Gli1 is a stronger transactivator than Gli2, also in
Figure 1 Maml1 interacts with Gli proteins and sustains Gli-mediated transcription. (a) Luciferase assay in HEK293T cells transfected with 12xGli-luc (left panel) or Patched1-
luc (right panel) reporter and different combinations of plasmids encoding for Maml1, Gli1 and Gli2 as indicated. Luciferase activity is expressed as fold induction relative to
pcDNA3 alone (empty control). (b) EndogenousGli1mRNA levels evaluated by qRT-PCR in NIH3T3 cells transfected with increasing amounts of Maml1, compared with pcDNA3.
(c) Coimmunoprecipitation (co-IP) experiments performed in HEK293T cells, transfected with expression vectors encoding for the indicated tagged proteins and
immunoprecipitated with anti-Flag without (IP) or with (Ctr) blocking peptide. The interaction with Gli1 and Gli2 was revealed with anti-HA (left panel) or anti-Myc (right panel),
respectively. (d) Reciprocal co-IP was performed by using anti-Gli1 antibody or control mouse antisera (IgG) and the interaction with Maml1 was detected with anti-Flag. Gli1 and
Maml1 protein levels in total cell lysates are shown. (e) Ptch1−/− MEFs were lysed and immunoprecipitated with Maml1 antibody or control rabbit antisera (IgG) and the blot was
reprobed with Gli1. (f) Representative immunofluorescence images of endogenous Gli1/Maml1 interaction in NIH3T3 cells analyzed by in situ proximity ligation assay (PLA).
Negative controls lacking one of the primary antibodies. No significant fluorescent signal was detected in NIH3T3 cells incubated with only one primary antibody (only Gli1; only
Maml1). Single plane confocal images were captured using a 60 × oil objective. Protein complexes were visualized in red; nuclei were DAPI labeled (blue). Scale bar: 100 μm. (g)
ChIP assay in HEK293T cells. PCR was performed using primers that amplify Gli consensus binding sites on human Ptch1 promoter (upper panel) as shown in schematic
representation (lower panel). According to Genomatix, basepairs in bold and underlined are important, since they appear in a position where the matrix exhibits a high
conservation profile (ci-value460); basepairs in capital letters denote the core sequence used by MatInspector. Dark circles represent predict binding sites. Data reported as
mean± S.D. **Pr0.01; ****Pr0.0001
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the presence of Maml1 (ref. 3). We examined whether Maml1
sustains the endogenous Gli1 transcriptional activity, the
readout of Shh activation pathway. Therefore, we monitored
Gli1 expression in NIH3T3 cells transfected with Maml1.
Figure 1b shows increasing expression levels of endogenous
Gli1 in a dose-dependent manner. The cooperation of Maml1
with Gli1 or Gli2 function suggests their physical association.
Figure 1c shows Gli1 and Gli2 in Maml1 immunoprecipitates,
indicating the formation of Maml1/Gli complexes, confirmed
also by reciprocal coimmunoprecipitation assay using anti-
Gli1 antibody (Figure 1d). To demonstrate endogenous Gli1/
Maml1 protein interaction, we used Maml1 immunoprecipi-
tates from Ptch1−/−MEF cells, with a constitutively active Shh
pathway (Figure 1e).29 Figure 1f also reveals the endogenous
Gli1/Maml1 complex in NIH3T3 cells by in situ proximity
ligation assay (PLA), detecting single interaction pairs of
native proteins by using antibodies directed against Maml1
and Gli1. Only interacting proteins pairing displays a red
signal by confocal microscopy. Indeed, a high degree of
Maml1/Gli1 interaction was observed both in cytoplasmic and
nuclear compartment. To determine the occupancy of the
Maml1/Gli complex on Shh target genes, we performed a
chromatin immunoprecipitation (ChIP) assay. Figure 1g
(upper panel) shows that both Maml1 and Gli1 are recruited
at the same Gli binding sites in the human Patched1
promoter, as shown in the schematic representation of
Figure 1g (lower panel). These data indicate that Maml1
physically interacts with Gli proteins and cooperatively they
activate specific Shh-responsive target genes.
Maml1 C-terminal region is required to allow its coopera-
tion with Gli1. To examine which region of Maml1 interacts
with Gli, we used truncated mutant Maml1 proteins (sche-
matic representation in Figure 2a) to perform coimmunopre-
cipitation assays. We focused on Gli1, the most powerful
effector of the Shh pathway, which is able to enhance its own
expression, autoreinforcing the signaling strength. We show
in Figure 2b that Gli1 is able to bind both the N-terminal
region (amino acids 1–302) and the C-terminal region (amino
acids 303–1016) of Maml1 protein, independently. This
observation suggests that Gli1 binds Maml1 at least in two
distinct domains. To determine which region of Maml1 is
important for the transcriptional activity of Gli1, we cotrans-
fected HEK293T cells with the combination of Gli1, Maml1
mutant forms and 12xGli- or Patched1-luc reporter con-
structs. Figure 2c shows that Maml1 full-length (FL) and
Maml1 124–1016 strongly enhance luciferase reporter gene
activity in the presence of Gli1 vector either on 12xGli-
promoter (upper panel) or Patched1 promoter (lower panel).
Conversely, the Maml1 COOH-terminal deleted mutant (1–
302) and the Maml1 303–1016 without the nuclear localiza-
tion signal (NLS) have no detectable effect on Gli1 transcrip-
tional activity. Interestingly, the Maml1 FL protein has been
previously shown to drive Maml1-interacting proteins, such
as Notch,17,30 p300 (ref. 31), MEF2C26 and GSK3β32 to the
nucleus, in particular into nuclear bodies.32 To this regard,
Maml1 mutant proteins appeared to exert a distinct influence
on Gli1 subcellular localization. In fact, Figure 2d shows that
Maml1 FL is able to address Gli1 into the nucleus, particularly
into nuclear bodies (panel h versus d). Instead, in cells
transfected with Maml1 124–1016, Gli1 completely diffuse
into the nucleus (panel p). Contrarily, Maml1 1–302 is not
able to address Gli1 into the nucleus (panel l) and Maml1
303–1016, deleted of the NLS domain, sequesters Gli1 into
the cytoplasm, where the two proteins preferentially interact
(panel t). Subcellular distribution of transiently transfected
Flag-tagged Maml1 FL and mutant forms is shown in
Supplementary Figure S2. Overall the data suggest that
Maml1 is required to sustain the nuclear localization of Gli1,
as further supported by the nuclear and cytoplasmic
fractionation assay (Supplementary Figure S3), and that
Maml1 COOH-terminal region is required to reinforce the
transcriptional activity of Gli1 in vitro.
Maml1 is required to fully activate Gli-mediated target
gene transcription. Overall, our data suggest that Maml1
influences Gli1 subcellular localization and acts as a
transcriptional coactivator strengthening the expression of
Gli target genes. To further support the model, we analyzed
whether Maml1 loss of function influences the transcriptional
activity of endogenous Gli1. Importantly, the small inter-
ference RNA (siRNA)-mediated depletion of Maml1 induces a
significant impairment of Gli1 protein expression (Figure 3a)
and Shh target genes, as Gli1 itself, Ptch1, Cyclin D1, Cyclin
D2 and Hip1 (Figure 3b).
Notably, Maml1 is a well-known transcriptional coactivator
of the Notch pathway and to exclude the possibility that Notch
signaling impairment might be responsible of the observed
effects, we investigated the expression of Hh target genes in
the presence of the γ-secretase inhibitor (DAPT) that blocks
the Notch pathway activation. We treated NIH3T3 cells with
DAPT that affects Notch1 activation, as revealed by using the
antibody against the valine 1744 (N1ICDVal1744) (Figure 3c, left
panel), and down-modulates its target gene, Hes1 (Figure 3c,
right panel). In contrast, quantitative real-time PCR (qRT-PCR)
assays reveal that Gli1 itself and Shh target gene expression
levels are not significantly modified by Notch inhibition
(Figure 3d), indicating that the role of Maml1 on Hh/Gli1
signaling is independent of the Notch activity. Accordingly,
Maml1 potently enhances Gli1 activity upon cotransfection
with 12xGli-luc (Figure 3e, left panel) or Patched1-luc
(Figure 3e, right panel), independently from the presence of
DAPT. Together these findings directly and functionally
connect Maml1 to the Shh pathway, suggesting a Maml1-
dependent reinforcement mechanism of Gli1 transcriptional
activity in a Notch-independent manner.
Maml1 deletion results in an impaired Shh signaling
cascade. To further validate that Maml1 functions as a
coactivator of Gli transcription factors, we used Maml1−/−
MEFs33 model. Interestingly, the absence of Maml1 gene
determines a significant reduction of endogenous Gli1
(Figures 4a, left panel and b) and Gli2 (Figures 4a, right
panel and b) expression levels in Maml1−/− MEFs, compared
with control. Moreover, the absence of Maml1 determines an
impaired activation of Shh signaling in Maml1−/− MEFs in
response to treatment with the Smo agonist, SAG.34
Figure 4c shows an important decrease of Shh target genes
expression, such as Gli1 itself, Ptch1 and Cyclin D1, in
Maml1−/− versus Maml1+/+ SAG-treated MEFs.
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Supplementary Figure S4 also shows reduced Gli1 expres-
sion levels upon SAG treatment in Maml1−/− respect to
control, in a time-dependent manner. To investigate the
requirement of Maml1 for Gli function, we used the Ptch1− /−
MEFs, in which Ptch1 deletion causes constitutive Gli
activation. Notably, the Maml1 silencing impairs Shh signal-
ing, by promoting the inhibition of Gli1 and Gli2 and specific
Shh target genes (Figure 4d), associated with a decreased
proliferation rate (Figure 4e), also revealed by MTT assay
(Figure 4f). These data further demonstrate that Maml1 is
Figure 2 Maml1 COOH-terminus plays a functional role on Gli1 activity. (a) Schematic representation of full-length (FL) and truncated Maml1 constructs. Transcription
activation domain (TAD): TAD1 (75–301 aa); TAD2 (303–1016 aa). (b) Whole-cell extract (WCE) from HEK293T cells cotransfected with indicated expressing vectors were
immunoprecipitated with anti-Flag (IP) or anti-Flag with blocking peptide (Ctr). Immunoprecipitates and aliquots of cell lysates (Total) were immunoblotted with the indicated
antibodies. (c) Luciferase assays of cotransfected HEK293Twith 12xGli-luc (upper panel) or Patched1-luc (lower panel) and different combinations of expression vectors, as
indicated. Luciferase activity is expressed as fold induction relative to control (pcDNA3). Data represent mean± S.D. ***Pr0.001; ****Pr0.0001. (d) Representative single
plane confocal immunofluorescence images of HEK293T cells cotransfected with indicated expression vectors. Flag- (green) or HA- (red) tags were visualized by confocal
microscopy. Confocal images were captured using a 60 × oil objective. Nuclei were DAPI labeled (blue). Scale bar: 10 μm
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functionally required to sustain full activation of Shh signaling,
by acting as a crucial coeffector also when the pathway is
constitutively activated.
Reduced GCPs proliferation correlates with a decreased
Gli activity in Maml1−/− mice. Shh signaling is a master
regulator of the development of cerebellar GCPs.8 To
investigate the relevant role of Maml1 in sustaining Shh
signaling in GCP cells, we measured endogenous Shh/Gli1
target genes in primary GCPs, derived from Maml1−/− and
control mice, by qRT-PCR analysis. Maml1−/− mice were
studied up to E19.5, since they die at perinatal period.
Figure 5a shows that the absence of Maml1 determines a
remarkable reduction of Gli1 target genes in Maml1−/− GCPs
when compared with Maml1+/+ littermates, associated with
an important decrease of Gli1 protein expression (∼39%)
(Figure 5b). To further investigate whether loss of Maml1
activity might result in a defective Shh signaling, we
measured the expression of the direct Shh target gene
Gli1 by qRT-PCR, upon SAG stimulation. Figure 5c shows
that the Gli1 activity is significantly reduced in GCPs of
Maml1−/−, when compared with wild-type (wt) mice.
Shh signaling supports the proliferation of GCPs during
cerebellar development.12,14 Thus, we examined whether the
absence of Maml1 can antagonize the mitogenic effect of Shh
on GCPs proliferation. For this purpose, we cultured GCPs
deriving from Maml1−/− and wt littermates, after SAG
treatment and pulsed with bromodeoxyuridine (BrdU) to label
Figure 3 Maml1 cooperates with Gli1 in a Notch-independent manner. (a) Proteins expression was detected by immunoblot analysis as indicated in WCE derived from
NIH3T3 cells transfected with Maml1 siRNA or control siRNA (scr). Anti-tubulin was used as a loading control (left panel). Optical densitometry (OD) analysis of Maml1 and Gli1
protein expression (right panel). (b) qRT-PCR analysis of Shh target genes in NIH3T3 48 h after silencing of Maml1 compared with control (scr). (c) WCE separated by SDS-page
from NIH3T3 upon 72 h treatment with DAPT or control vehicle (DMSO). To reveal the activated form of Notch1, an anti-Notch1 Val 1744 antibody was used (left panel).
Expression level of Hes1 mRNA was evaluated by qRT-PCR (right panel). (d) Expression levels of Shh target genes evaluated by qRT-PCR in DAPT or DMSO (Ctr) treated
NIH3T3 cells. (e) Luciferase assays in HEK293T cells cotransfected with 12xGli-luc (left panel) or Patched1-luc (right panel) and different combinations of expression vectors as
indicated. After DAPT or control vehicle treatment, cell lysates were harvested for luciferase assay. Data represent mean± S.D. NS, not significant; **P≤ 0.01; ***P≤ 0.001;
****P≤ 0.0001
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proliferating cells. Intriguingly, only a small percentage of
Maml1−/− GCPs incorporates BrdU (Figure 5d), with nearly
3-fold decrease in BrdU-positive cell number (Figure 5e).
Moreover, Figure 5f shows a reduced endogenous Pcna
(proliferating cell nuclear antigen) expression in Maml1−/−
GCPs, which correlates to a decrease in number of total
cerebella-derived GCPs in E19.5 Maml1−/− mice (Figure 5g).
To discriminate the role sustained by Shh and Notch
signaling in GCPs, we performed specific pharmacological
treatments in order to compare the outcomes of these signaling
pathways on cerebellar progenitors proliferation. Firstly, we
evaluated the expression of Notch pathway genes in GCPs.
Supplementary Figure S5a shows that Notch receptors and
specific target genes are similarly expressed in Maml1−/− and
Maml1+/+GPCs, except for Hes1, which appears decreased in
Maml1−/−. Noteworthy, Hes1 has been described to be also an
Shh signaling target.35 Then, we performed BrdU assay in
SAG-activated Maml1+/+ GCPs, treated with DAPT or KAAD/
cyclopamine.36 Interestingly, Supplementary Figures S5b and
c show that KAAD/cyclopamine treatment impairs GCPs
proliferation with a significant effect, when compared with
DAPT, and this is associated with an important downregulation
of Shh/Gli1 target genes (panel d).
Furthermore, Supplementary Figure S6a shows that the
proliferation of DAPT-treated Ptch1− /− MEFs, revealed by
MTTanalysis, is more preserved, when compared with KAAD/
cyclopamine treatment, suggesting that Notch pathway plays
a marginal role in controlling the proliferation on Hh-activated
cells. In addition, the inhibition of Notch pathway by DAPT
does not influence the expression of Shh target genes
(Supplementary Figures S6b and c), as instead does the
KAAD treatment (Supplementary Figures S6b and d). Notably,
Supplementary Figure S6b confirms Hes1 as a common
target gene of Notch and Shh pathways.35
Cerebellar defects in Maml1−/− mice. Shh signaling plays
a critical role and regulates the complexity of cerebellar
foliation.10,14 To establish whether the decreased proliferation
Figure 4 Maml1 loss of function determines an impaired Shh signaling pathway. (a) Immunoblot analysis of WCE from Maml1-deficient (Maml1−/−) and control (Maml1+/+)
MEFs, using the indicated antibody. (b) Optical densitometry (OD) analysis of Maml1, Gli1 and Gli2 protein expression evaluated by immunoblotting, related to panel (a). (c)
Representative qRT-PCR analysis of Hh target genes inMaml1−/−MEFs compared with control upon SAG treatment for 48 h. The data are presented as fold of activation respect
to DMSO. (d) qRT-PCR analysis ofMaml1mRNAs and Shh target genes in Ptch1−/−MEF cells transfected with Maml1 siRNA or control siRNA (scr) for 48 h. (e) Trypan blue cell
counting to determine the rate of proliferation and the number of viable cells in Ptch1−/− MEFs after transfection with Maml1 siRNA for 48 h, compared with scramble (scr). (f)
MTT cell proliferation assay in Ptch1−/− MEF cells Maml1-silenced compared with control. The data are presented as fold of reduction respect to scramble. Data represent
mean± S.D. **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001
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observed in GCPs derived from Maml1−/− mice may
negatively impact on the foliation pattern, histological
sections of cerebella at E18.5 and E19.5 were stained with
hematoxylin and eosin (H&E). Figure 6a shows a defective
foliation pattern in Maml1−/− cerebella at E18.5 with slight
indentations corresponding to preculminate (pc) and primary
(pr) cardinal fissures; furthermore, the cardinal lobes are not
identifiable, with respect to control (panel B versus A).
Sagittal sections of cerebella at E19.5 in Figure 6a show that
in wild-type mice the four principal fissures are formed, as
well as two additional fissures. In contrast, E19.5 Maml1−/−
mice have only two primary fissures (pc and pr), although
they are very shallow (panel D versus C). Of note, the
posterolateral and secondary fissures are not visible,
Figure 5 Reduced GCPs proliferation correlates with impaired expression of Shh target genes inMaml1−/−mice. (a) qRT-PCR analysis shows mRNA expression level of Shh
target genes in GCP cultures fromMaml1−/− and control mice. (b) GCPs from E19.5Maml1+/+ (blue) andMaml1−/− (green) mice were analyzed by flow cytometry analysis with
a specific anti-Gli1 antibody or IgG, used as a isotype control. (c) GCPs from E19.5Maml1−/− and control littermates cerebella were treated with SAG or vehicle alone (DMSO) for
24 h. Endogenous Gli1 mRNA expression level was determined by qRT-PCR analysis. The results were analyzed as fold of activation, compared with control (DMSO). (d) BrdU
incorporation assay in SAG-treated Maml1+/+ and Maml1−/−GCPs at E19.5 after a 24 h BrdU pulse. Proliferating cells are visualized in red; nucleus was labeled in blue. Scale
bar: 200 μm. (e) Mitotic index was calculated by number of BrdU-positive GCPs/total GCPs. The results were analyzed as fold of reduction respect to control cells. (f) qRT-PCR
analysis of Pcna, an Shh target involved in cellular proliferation, in ex vivo GCP cultures fromMaml1−/− and control mice. (g) Trypan blue cell counting was performed to estimate
the growth rate of viable cells obtained from GCP cultures from Maml1+/+ (n= 23 mice) and Maml1−/− (n= 21 mice) at E19.5. The box plot shows the distribution of cellular
counts. Data represent mean±S.D. *P≤ 0.05; **PP≤ 0.01; ***PP≤ 0.001; ****P≤ 0.0001
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corresponding to regions with a highest Shh signaling.12,14
Then, we performed immunostaining assay with PCNA,
confirming that the cells from Maml1−/− cerebellum are less
mitotically active than in control (Figures 6b and c), in
particular in correspondence of secondary and posterolateral
fissures (C versus A and D versus B). The shallow principal
fissures at E18.5 and delayed lobularization of Maml1−/−
cerebella are reminiscent of foliation defects observed in
mice with altered Shh signaling.13,14 In addition, morpho-
metric analysis reveals that the perimeter and total
area of Maml1−/− cerebella are reduced, suggesting that
Maml1 depletion negatively affects cerebellar size
(Figure 6d). Overall, these results support our hypothesis
that Maml1 protein is critical to mediate Shh signaling
with an impact on cerebellum size and foliation during
development in vivo.
Discussion
Our findings unveil an additional mechanism of regulation of
Shh pathway by identifying a novel role for Maml1 as a
coactivator of Gli transcription factors. Maml proteins exhibit
distinct expression patterns during embryonic development,
supporting the hypothesis that they play specific roles in
different tissues.20,37 We analyzed Maml1 expression in
Baseline Atlas38 and observed that the cerebellum is the
district with the highest expression levels of Maml1, compared
with other human tissues (Supplementary Figure S1a),
suggesting an important role in this organ. Notably, using
both in vitro and in vivo approaches, we found that Maml1
empowers Shh signaling, by modulating Gli1 and Gli2 activity.
Noteworthy, coexpression of Maml1 and Gli1 or Gli2 con-
siderably activates Gli target promoters, where Gli1 exhibits a
stronger transcriptional activity than Gli2, also in the presence
Figure 6 Maml1−/− mutant mice present foliation defects in developing cerebellum. (a) Midsagittal sections of E18.5 and E19.5 Maml1−/− and control cerebella stained with
H&E. The four principal fissures (denoted by asterisks) as well as two additional fissures (indicated by the arrows) are shown in the figure. Abbreviations: prc, precentral; pc,
preculminate; pr, primary; pp, prepyramidal; sec, secondary; pl, posterolateral fissures; ABL, anterobasal; ADL, anterodorsal; CEL, central; POS, posterior; INL, inferior lobes.
Images of each panel were taken at the same magnification. Scale bar: 250 μm. (b) Immunohistochemical staining for PCNA in midsagittal cerebellar sections from Maml1+/+
and Maml1−/− mice at E19.5 (left panels). Scale bar: 250 μm. High magnification images of PCNA staining in the EGL, corresponding to posterolateral (A, C) and secondary
(B, D) fissures (right panels). Scale bar: 50 μm (c) Graph shows the number of PCNA-positive cells, analyzed as fold of reduction in comparison withMaml1+/+ control mice. Five
sections/mouse n= 3 mice per group were analyzed. ****P≤ 0.0001 (d) Quantitative analyses of cerebellar morphology. Values of perimeter (upper) and area (lower) of
midsagittal cerebella sections from three mice of each genotype are represented in the graphs (left panels). Littermates are indicated with the symbol of the same color.
The histograms (right panels) show Maml1−/− cerebellum perimeter (upper) and area (lower), represented as fold of reduction compared with control. *P≤ 0.05
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of Maml1. Moreover, increasing amounts of Maml1 reveal a
significant dose-dependent upregulation of Gli1 transcripts,
indicating that Maml1 is able to reinforce endogenous Shh
pathway. In most of our experiments, we focused on Gli1,
since it is the strongest transcriptional activator and the final
effector of Shh signaling, being endogenously activated by
Gli2 (refs 5, 39). Our results clearly show a robust synergistic
association between Maml1 and Gli1 able to drive down-
stream transcriptional events of the Shh signaling cascade.
Significantly, Maml1 loss of function in NIH3T3 or in
constitutively activated Shh pathway-bearing Ptch1−/− MEFs
determines a significant downmodulation of Gli target genes.
This indicates that the Shh signaling activity is significantly
downregulated in the absence of Maml1, with a negative
impact on cell proliferation. Outstandingly, the absence of
Maml1 significantly impairs the Shh signaling, as revealed not
only by reduced expression levels of Gli1 and Gli2 in MEFs
and GCPs from Maml1−/− mice but also by a disrupted Gli
activity when the pathway is activated, upon treatment with the
specific Smo agonist, SAG.
Shh/Gli signaling represents the master regulator of the
proliferation of GCPs.11,40 Increasing data support the notion
that Shh and its transcriptional mediators, Gli1 and Gli2,
regulate not only GCPs proliferation in vivo, but also influence
the foliation, the final size and the shape of the cerebellum
lobes.12,13 Shh expression from E17.5 to early postnatal
stages is spatially restricted to the regions where fissures form
first.14 Indeed, by removing Shh receptor, Smoothened or Gli1
and/or Gli2, the extent of foliation is significantly reduced,
correlating with a decrease in GCPs proliferation. Mice lacking
Gli1 appear phenotypically normal;41 however, the importance
of this protein in cerebellum development is demonstrated by
the observation that loss of Gli1 enhances the foliation defects
of the Gli2-deficient cerebellum.42 Our data demonstrate that
Maml1−/− mice exhibit a disrupted Shh signaling with a
significant downregulation of Gli1 and Gli2 and a reduced
responsiveness to SAG. Our findings show that the impaired
Shh signaling in Maml1−/− GCPs results in a dramatic
reduction of GCPs proliferation. Onward the decreased
number of GCPs, we show an impaired foliation process in
Maml1−/− cerebella at E18.5 and E19.5, with almost complete
lack of secondary and posterolateral fissures, corresponding
to regions with the highest Shh signaling, characterized by
fissures appearing very shallow. Therefore, Maml1−/− pheno-
type is reminiscent of cerebella from mice with a reduced Shh
signaling.12,14 As GCPs expansion is a driving force of
foliation,15 the reduced number of GCPs in Maml1−/−
cerebellum explains, at least in part, the foliation defects
observed in these mice. Hence, Maml1 depletion severely
perturbs Shh signal transduction and mimics aspects of Shh
pathway deficiency with impaired GCPs proliferation, cere-
bellar foliation and size, suggesting an intrinsic requirement for
Maml1 in cerebellum development. Our observations would
support the notion that Maml1 is necessary to potentiate the
Hedgehog pathway when a strong Hh signaling is required
during development, as previously suggested in Drosophila
follicle stem cells.43
Of note, the inhibition of Notch signaling pathway, using the
γ-secretase inhibitor DAPT, does not affect the action of Maml1
on Gli1, suggesting that the role of Maml1 is Notch activation
independent. Noteworthy, N-terminus of Maml1 is important
for interaction with Notch and proteins of other signaling
pathways, as MEF2C and p53 or with the coactivator p300.
Conversely, we show that the N-terminal region of Maml1 is
dispensable to sustain Gli1-mediated transcription, further
supporting our hypothesis that the action of Maml1 on Gli1 is
Notch-independent.
Notably, pharmacological inhibition of Shh and Notch
signaling underlines different biological outcomes on GCPs
and Ptch1−/− MEFs, where Shh pathway shows a predomi-
nant effect in sustaining the proliferation compared with Notch
signaling. Moreover, the observation that DAPT treatment is
able to promote the Gli1 and Gli2 expression allow us to
speculate that the Notch inhibition may indirectly regulates the
Hh pathway by a dynamic competition for the same
coactivator, Maml1. Overall these observations suggest that
Maml1 represents a new link between Notch and Hh signaling
pathways.
In conclusion, we provide a new integrated level of
regulation in Shh/Gli pathway by identifying Maml1 as a novel
coactivator that empowers Shh signaling with important
implications on GCPs proliferation and an impact on
cerebellum development.
Noteworthy, aberrant Shh pathway activation is associated
with various disorders, including medulloblastoma, the most
common brain tumor in childhood affecting cerebellum.16,44–46
The in silico analysis reported in Differential Atlas database
shows that Maml1 expression increases in Shh-dependent
medulloblastoma, when compared with healthy cerebellar
tissue or other medulloblastoma subtypes (Supplementary
Figure S1b). Thus, Maml1 could represent an attractive
druggable target for future therapeutic approaches directed
against Shh-driven tumors.
Materials and Methods
Mice. The generation and typing of Maml1−/− mouse have been described
elsewhere.33 Mice were maintained on a C57BL/6 background; they were bred and
held under specific pathogen-free conditions in animal facility. The studies involving
animals have been conducted following the Italian national guidelines for use and
care of experimental animals, established in D.Lgs. n.26/2014, and in accordance
with European Directive 2010/63/UE.
Cell culture, proliferation assay and treatments. NIH3T3, HEK293T
and wild type and Ptch1−/−MEFs were maintained as described elsewhere.47
Primary wild type and Maml1−/− MEFs were isolated from E13.5 littermates
embryos, following the protocol from Xu.48 Primary granule cell precursor (GCPs)
cells were cultured from E19.5 cerebella, according to established protocols40,49 and
after 3 h the medium was replaced for the starvation in serum-free medium and the
cells were treated with 200 nM SAG or vehicle alone (DMSO). Cell proliferation was
evaluated by BrdU-Labeling and Detection Kit (cat.#11296736001; Roche, Welwyn
Garden City, UK), as previously described.50 Nuclei were counterstained with
Hoechst reagent and images were acquired with an Axio Vert.A1 microscope and
analyzed with Axio Vision LE64 Software (Carl Zeiss Microscopy GmbH, Jena,
Germany). At least 500 nuclei were counted in triplicate and the number of BrdU-
positive nuclei respect to total cells number was evaluated to calculate the
proliferation rate. To analyze the cell growth rate in Ptch1−/− MEFs, 2500 cells per
well were plated onto a 96-well plate. The WST1 solution (cat.#5015944001;
Roche) was added to each well according to the manufacturer’s instructions.
Spectrophotometric absorbance at 450 nm wavelength was determined by the plate
reader GloMax-Multi Detection System (Promega, Madison, WI, USA). Cells were
treated with different compounds: 10 μM γ-secretase inhibitor IX (DAPT, cat.
#565770; Calbiochem, Merck Millipore, Darmstadt, Germany), 200 nM Smoothened
agonist (SAG, cat.#ALX-270-426-M001; Enzo Life Sciences, Farmingdale, NY, USA)
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and 1 mM KAAD/cyclopamine (Shh pathway inhibitor) (cat.#239804; Calbiochem),
for the times indicated in the figures. All compounds were dissolved in sterile
DMSO, and DMSO was used in control treatments. Before SAG treatments, cell
cultures were subjected to serum starvation.
Cell transfection, luciferase assay and plasmids. Transient transfec-
tion of HEK293T and NIH3T3 cell lines were performed using Lipofectamine 2000
(Life Technologies, Carlsbad, CA, USA) or TransFectin Lipid Reagent (Bio-Rad,
Hercules, CA, USA), according to the manufacturer’s instructions. Luciferase
Assays were performed using the indicated reporter plasmids with different
combinations of expression vectors, as shown in figures. pRL-TK Renilla was used
as normalization control and pcDNA3 as control empty vector. Luciferase activity
was assayed with a Dual Luciferase Assay system (Promega) as described
previously.51 All luciferase activity data are presented as means± S.D. of value from
at least three independent experiments, each performed in triplicate. The following
plasmids were described elsewhere: human Patched1 promoter (Patched1-luc) and
promoter 12GLI-RETKO-luc (12xGli-luc);52 pCS2-HA3-Gli1 (ref. 53), pCS2-MT
Gli2FL-Myc,54 pFLAG-CMV-2 Maml1 full-length (1–1016) (ref. 51), pFLAG-CMV-2
Maml1 (1–302) and pFLAG-CMV-2 Maml1 (124–1016) (ref. 17). cDNA
corresponding to Maml1 303–1016 was amplified by PCR from pFLAG-CMV-2
Maml1 full-length (1–1016) and cloned as SalI/NotI fragment in pFLAG-CMV-2
(#E7033 Sigma-Aldrich).
siRNA silencing. siRNA was performed using 100 nM SMART pool siRNA
duplexes (cat.#L-059179-01-0005 for Maml1) or 100 nM scrambled control (cat.
#D-001810-10-20) purchased by Dharmacon Inc. (Lafayette, CO, USA), using
Lipofectamine RNAiMAX (Life Technologies), according to the manufacturer’s
instructions.
Reverse transcription PCR /qRT-PCR. Total RNA extraction and reverse
transcription PCR (RT-PCR) were previously described.55 Extraction and reverse
transcription of mRNA from GCPs was achieved through the use of Cells-to-CT
1-Step TaqMan Kit (Life Technologies, Carlsbad, CA, USA), according to the
manufacturer’s instructions. Analysis of gene expression were realized by qRT-PCR
using TaqMan designed assays on demand (Invitrogen, Life Technologies) for the
specific target genes, reported in Supplementary Table S1, on the StepOnePlus
Real-Time PCR System (Applied Biosystems, Life Technologies), following the
manufacturer’s protocol for the comparative CT method. mRNA quantification was
expressed, in arbitrary units, as a ratio of sample quantity to the mean value of
control sample. Normalization was carried out using hypoxanthine guanine
phosphoribosyl transferase (Hprt) as internal control gene.
Protein extract, immunoprecipitation and immunoblot analysis.
Preparation of whole-cell lysates, fractionation of cytoplasmic and nuclear proteins
and immunoprecipitation assays were performed as described elsewhere.56 Briefly,
for coimmunoprecipitation in transfected HEK293T cells, cell lysate were incubated
with agarose conjugate Flag M2 beads (cat.#A2220; Sigma-Aldrich, St. Louis, MO,
USA) for 2 h at 4 °C. In control sample the antibody was saturated with anti-Flag
peptide (cat.#F4799; Sigma-Aldrich). For reciprocal immunoprecipitation assay, after
a pre-clearing step with Protein G-Agarose (cat.#sc-2002; Santa Cruz Biotechnol-
ogy, Dallas, TX, USA), cell lysate was incubated with anti-Gli1 (C-1) (cat.#sc-
515751; Santa Cruz Biotechnology) or normal mouse IgG (cat.#sc-2025; Santa
Cruz Biotechnology) as control for overnight at 4 °C. The complexes were
precipitated with Protein G-Agarose, then the beads were washed extensively with
wash buffer and the interaction was evaluated by western blot analysis. Similarly, for
Ptch1−/− MEFs the coimmunoprecipitation was realized with anti-Maml1 (D3E9)
(cat.#11959; Cell Signaling, Danvers, MA, USA) or normal rabbit IgG (cat.#sc-2027;
Santa Cruz Biotechnology) as control for overnight at 4 °C; the pre-clearing step
and precipitation of complexes were realized with Protein A-Agarose (cat.#sc-2001;
Santa Cruz Biotechnology). For immunoblot analysis the following primary
antibodies were used: anti-Gli1 (L42B10) (cat.#2643), anti-Maml1 (D3E9) and
anti-Notch1 (Val 1744) (D3B8) (cat.#4147) purchased from Cell Signaling; anti-Flag
(cat.#F3165), anti-Myc (cat.#M4439), anti-Notch2 (Val1697) (cat.#SAB450200) and
anti-β-Actin (cat.#A5441) from Sigma-Aldrich; anti-HA (cat.#sc-7392), anti-α-Tubulin
(cat.#sc-8035) and anti-Lamin B (M20) (cat.#sc-6217) from Santa Cruz
Biotechnology; anti-Gli2 (cat.#AF3635) from R&D Systems (Minneapolis, MN,
USA). Bound antibodies were detected with enhanced chemiluminescence (ECL kit;
Amersham, GE Healthcare, Lafayette, CO, USA). The intensity of protein
expression was quantified using Quantity One Analysis Software (Bio-Rad). Values
were normalized to housekeeping protein expression and represented as relative
levels with respect to control sample.
Chromatin immunoprecipitation. ChIP was performed as described
earlier.57,58 Immunoprecipitated DNA from HEK293T with Gli1 (H300) (cat.#sc-
20687; Santa Cruz Biotechnology) or Maml1 (D3E9) or IgG (normal rabbit IgG)
antibodies was eluted and analyzed by semiquantitative PCR, using a primer set
encompassing two predicted binding sites for Gli zinc finger family (V$GLIF Matrix
Family) (from − 538 to − 521; from − 461 to − 445, corresponding to dark circles in
Figure 1f, low panel), on human Patched1 promoter (GXP_227868, from − 891 to
− 87 relative to start codon). Human Patched1 promoter was identified using
MatInspector (Software GmbH, Munich, Germany). The primer set used to
specifically amplify Gli binding sites is the following: 5′-GAACCCAGCAGCCAGAGC
-3′ and 5′-CGACCCCTTCACTGCAGAA-3′.
Immunostaining and confocal imaging. Immunofluorescence staining of
HEK293T cells was performed as described elsewhere.51 Twenty-four hours after
transfection, the cells were stained with primary antibody: mouse anti-HA (cat.
#MMS-101 P; Covance, Princeton, NJ, USA) and rabbit anti-Flag (cat.#F7425;
Sigma-Aldrich). The secondary antibodies used were Alexa Fluor 594- and 488-
conjugated respectively anti-mouse and anti-rabbit (Molecular Probes, Life
Technologies). Nuclei were counterstained with Hoechst reagent. Single plane
confocal images in the center of the cell were acquired using an inverted Olympus
iX73 microscope equipped with an X-light Nipkow spinning-disk head (Crest Optics,
Rome, Italy) and Lumencor Spectra X Led illumination. Images were collected using
a CoolSNAP MYO CCD camera (Photometrics, Tucson, AZ, USA) and MetaMorph
Software (Molecular Device, Sunnyvale, CA, USA) with a × 60 oil objective.
Proximity ligation assay. In situ PLA was performed in NIH3T3 cells using the
Duolink In situ-Fluorescence Technology, Olink Bioscience (Sigma-Aldrich). All the
steps were performed according to the manufacturer’s protocol. Primary antibodies:
anti-Gli1 (H300) and anti-Maml1 (N-20) (cat.#sc-18506) from Santa Cruz
Biotechnology. Hybridization between the two PLA anti-rabbit PLUS and anti-goat
MINUS probes leading the fluorescent red signal only occurs when the distance
between the two antigens is less than 40 nm. In control experiment, cells were
incubated with only one primary antibody and no significant binding was detected (only
Gli1; only Maml1). Single plane confocal images were acquired using an inverted
Olympus iX73 confocal microscope as described in immunofluorescence staining.
Immunohistochemistry. Cerebella from E18.5 and E19.5 mice were
collected and tissues were fixed in 4% formalin and paraffin embedded. Consecutive
sections (2 μm thick) were stained with H&E. Immunocytochemical assay was
performed using an anti-PCNA antibody (cat.#ab15497; Abcam, Cambridge, UK).
Detection was carried out with Mouse-to-Mouse HRP (DAB) staining system (cat.
#MTM001-IFU; ScyTek Laboratories, Logan, UT, USA), according to the
manufacturer’s instructions. Images were acquired with a Leica DM1000 microscope
equipped with a ProgRes Speed XTcore 3 CCD camera and collected using ProgRes
CapturePro 2.8 software (Jenoptik Optical Systems GmbH, Jena, Germany).
Proliferation index was deduced by the count of PCNA-positive GCPs/total GCPs in
EGL of wild type and Maml1−/− cerebella. The midsagittal area and perimeter of
cerebella were measured from pictures captured using Aperio ImageScope (Aperio,
Leica Biosystems, Wetzlar, Germany) image analysis software.
Cytofluorimetric analysis. Freshly isolated GCP cells from cerebellum were
stained and analyzed on a FACS-Calibur with CellQuest software (BD Biosciences,
San Jose, CA, USA). For Gli1 intracellular staining, BD Fixation/Permeabilization kit
was used (cat.#554714; BD Biosciences) and cells were incubated with anti-Gli1
antibody (L42B10) (cat.#2643; Cell Signaling) or normal mouse IgG (cat.#sc-2025;
Santa Cruz Biotechnology), used as a negative control.
Statistical analysis. All results were reported as the mean± S.D. of at least
three independent experiments, each performed in triplicate. Student’s t-test for
unpaired samples was used to assess differences among groups. A P-valueo0.05
was considered statistically significant (NS P40.05; *P≤ 0.05; **P≤ 0.01;
***P≤ 0.001; ****P≤ 0.0001).
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